Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Format: Virtual Presentation and 1x1 Investor Meetings
Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1

The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation  

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.  

Media Contact:
Gina Nugent 
Nugent Communications 
617-460-3579 
gina@nugentcommunications.com

Investor Contacts: 
Laurence Watts 
Gilmartin Group 
619-916-7620 
laurence@gilmartinir.com

or

Kiki Patel, PharmD 
Gilmartin Group 
332-895-3225
kiki@gilmartinir.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.